Experimental Drug Tolinapant Boosts Immunotherapy Response in Advanced Solid Tumors
A phase I trial found that the IAP antagonist tolinapant combined with pembrolizumab was well tolerated and produced a 33 ...
A phase I trial found that the IAP antagonist tolinapant combined with pembrolizumab was well tolerated and produced a 33 ...
In recent groundbreaking research published in Molecular Cancer, scientists have illuminated the intricate relationship between immune cell senescence and the ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine